MERCANS
22.12.2023 15:10:28 CET | Business Wire | Press release
Avasant, a globally recognized analyst firm, has named Mercans as a payroll process transformation leader in its annual RadarView assessment of 2022-2023. Mercans clearly stood out among the 27 providers assessed for consistently delivering exceptional value to the market. Avasant's comprehensive industry analysis categorizes providers into challengers, disruptors, innovators, and leaders. Avasant placed Mercans in an elite group of industry leaders, confirming its technology leadership role in the global payroll industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231222991924/en/
Mercans Emerges as a Payroll Business Process Transformation Leader in Avasant's RadarView (Photo: AETOSWire)
In a span of one year, Mercans transitioned from a disruptor to an industry leader in Avasant’s assessment, demonstrating its impressive progress across all RadarView’s critical excellence dimensions - practice maturity, domain ecosystem, and investments and innovation.
Avasant's meticulous research methodology, incorporating publicly available information, SEC filings, annual reports, executive interviews, product demos, and direct inputs from service providers, adds depth and credibility to the acknowledgment of Mercans' industry leadership.
Avasant highlights Mercans' strategic approach and states: Leveraging its proprietary payroll engine and in-house local experts, Mercans delivers services across 160 countries. Mercans boasts a distinctive practice size, serving multinational corporations and Fortune 500 companies, supporting over 40 languages. The company's global delivery infrastructure spans 121 local offices, contributing to an impressive payroll revenue growth of over 30% from June 2022 to June 2023, reflecting its financial robustness.
At the heart of Mercans' success lies its proprietary global payroll platform - HR Blizz, the only gross-to-net payroll application that allows generating statutory compliant payrolls worldwide in a single software.
Mercans has disrupted the global payroll landscape with its G2N Nova global payroll engine. This state-of-the-art payroll engine stands out as the sole stateless application globally, swiftly generating payroll calculations across 160 countries within seconds, all while avoiding the storage of any sensitive employee data. This innovative approach has positioned G2N Nova as a catalyst for multinational corporations seeking to fully digitize their global payroll operations. Beyond its uniqueness as the sole global gross-to-net payroll application, G2N Nova offers a fully autonomous and touchless payroll experience, leading to dramatic reductions in processing times and costs.
Aditya Jain, Principal Analyst at Avasant, comments, "Mercans has developed its native global payroll engine to facilitate gross-to-net payroll calculations, digitalize processes, and offer self-service functionality to employees in 160 countries worldwide. Its partnerships with HCM and ancillary HR platform vendors enable it to offer comprehensive HR services through a unified portal. It leverages its local delivery network, including offices and regional experts in 121 countries, to help enterprises reduce dependence on local payroll aggregators for last-mile services across countries.
"Its continued investments in technology innovation, such as no-code HR integration tools and instant payments functionality, flexible business models, and a global delivery network, have made Mercans a leader in Avasant’s Payroll Business Process Transformation 2023–2024 RadarView."
About Mercans
Mercans is a global leader in payroll technology. Mercans’ revolutionary global payroll platform HR Blizz enables SMBs and enterprise businesses to manage payrolls across 160 countries. With 20 years of global payroll expertise, Mercans delivers the full spectrum of HR services through a single, secure global platform.
Visit www.mercans.com
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231222991924/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom